The cardiovascular effects of novel weight loss therapies

Graphical Abstract Current evidence on the effect of each obesity intervention on weight, cardiovascular risk factors, and cardiovascular outcomes, along with indications for the use of these interventions. Tirzepatide not yet approved for weight management in EU but has completed Phase 3 weight loss trials and has ongoing cardiovascular outcome trials in patients with obesity. Weight losses displayed are estimates. AE, adverse event; BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; GI, gastrointestinal; OD, once-daily; OTC, over-the counter; OW, once-weekly; SBP, systolic blood pressure; SQ, subcutaneous; T2D, Type 2 diabetes; TID, three times daily. The prevalence of overweight and obesity has reached pandemic proportions. Obesity is known to increase the risk for Type 2 diabetes and hypertension, as well as the risk for overt cardiovascular (CV) disease, including myocardial infarction, heart failure, and stroke. The rising prevalence of obesity may counteract the recent advances in primary and secondary prevention of CV disease. Overweight and obesity are common in patients with CV disease; however, cardiologists face several challenges in managing body weight in this population. Many may not consider obesity as a therapeutic target probably because there were no previous highly effective and safe pharmacologic interventions to consider. In addition, they may not have the expertise or resources to implement lifestyle interventions and may have limited familiarity with obesity pharmacotherapy. Moreover, the long-term CV effects of obesity pharmacotherapy remain uncertain due to limited CV outcome data with weight loss as the primary intervention. Although current CV guidelines recognize the importance of weight loss, they primarily focus on lifestyle modifications, with fewer details on strategies to utilize obesity pharmacotherapy and surgery. However, the recent 2022 American Diabetes Association/European Association for the Study of Diabetes consensus on the management of Type 2 diabetes has moved up weight management to the front of the treatment algorithm, by prioritizing the use of pharmacologic interventions such as glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, which have potent weight-lowering effects, in addition to glucose-lowering effects. This review appraises the current evidence regarding the CV effects of weight-loss interventions. Considering this evidence, practical guidance is provided to assist cardiologists in developing and implementing treatment plans, which may allow optimal weight management while maximizing CV benefits and minimizing side effects to improve the overall well-being of people with CV disease.

Automated summary

This study investigates the cardiovascular effects of weight-loss interventions and provides practical guidance for cardiologists in developing and implementing treatment plans.